News Column

Study Results from German Cancer Research Center Provide New Insights into Immunotherapy (IMA901 for metastatic renal cell carcinoma in the context...

July 28, 2014



Study Results from German Cancer Research Center Provide New Insights into Immunotherapy (IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy)

By a News Reporter-Staff News Editor at Clinical Oncology Week -- Current study results on Biotechnology have been published. According to news reporting out of Heidelberg, Germany, by NewsRx editors, research stated, "The promising option of immunotherapy for metastatic renal cell carcinoma has evolved from rather unspecific approaches to a specific activation of an anti-tumor T-cell response."

Our news journalists obtained a quote from the research from German Cancer Research Center, "The latest step is a synthetic peptide vaccine called IMA901, which demonstrated a clear association between a provoked T-cell response and a prolonged overall survival. The results of IMA901 for the treatment of metastatic renal cell carcinoma are discussed together with new approaches to immunotherapy, such as local and systemic immunomodulation with adjuvants, checkpoint inhibitors, classical chemotherapeutics, such as cyclophosphamide or tyrosine kinase inhibitors."

According to the news editors, the research concluded: "The capability of theses substances to modulate leukocytes subsets, such as myeloid-derived suppressor cells, Tregs or Th17 cells, are outlined together with the possibility to combine them with tumor vaccination strategies to achieve a higher cancer specificity and immunogenicity."

For more information on this research see: IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncology, 2014;10(6):937-948. Future Oncology can be contacted at: Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England (see also Biotechnology).

Our news journalists report that additional information may be obtained by contacting S. Rausch, German Canc Res Center, German Canc Consortium DKTK, Heidelberg, Germany. Additional authors for this research include S. Kruck, A. Stenzl and J. Bedke.

Keywords for this news article include: Heidelberg, Germany, Europe, Biotechnology, Carcinoma, Immunomodulation, Immunotherapy, Kidney, Nephrology, Oncology, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Oncology Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters